Fungal infections 1

Fungal infections in HIV/AIDS

Andrew H Limper, Antoine Adenis, Thuy Le, Thomas S Harrison

Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS. Systemic infections are mainly with *Pneumocystis jirovecii* (pneumocystis), *Cryptococcus neoformans* (cryptococcosis), *Histoplasma capsulatum* (histoplasmosis), and *Talaromyces (Penicillium) marneffei* (talaromycosis). The incidence of systemic fungal infections has decreased in people with HIV in high-income countries because of the widespread availability of antiretroviral drugs and early testing for HIV. However, in many areas with high HIV prevalence, patients present to care with advanced HIV infection and with a low CD4 cell count or re-present with persistent low CD4 cell counts because of poor adherence, resistance to antiretroviral drugs, or both. Affordable, rapid point-of-care diagnostic tests (as have been developed for cryptococcosis) are urgently needed for pneumocystosis, talaromycosis, and histoplasmosis. Additionally, antifungal drugs, including amphotericin B, liposomal amphotericin B, and flucytosine, need to be much more widely available. Such measures, together with continued international efforts in education and training in the management of fungal disease, have the potential to improve patient outcomes substantially.

Introduction

Fungi contribute greatly to opportunistic infections in patients with late-stage HIV infection. *Pneumocystis jirovecii* is the most common cause of respiratory infection and *Cryptococcus neoformans* the most common cause of CNS infection in patients with AIDS across large parts of the world. *Histoplasma capsulatum* (especially common in parts of the Americas) and *Talaromyces* (formerly *Penicillium*) *marneffei* (endemic in south and southeast Asia) are thermally dimorphic fungi that cause disseminated infections.

In this Series paper, we review the epidemiology and progress in diagnosis and therapy for these four major systemic fungal pathogens in patients with HIV/AIDS. We cite the most relevant recent papers, but additional supplementary references are available online, organised by section (appendix).

Although we focus on these major infections, other fungi are also important in patients with HIV/AIDS. *Coccidioides* spp especially affect patients with AIDS in the Americas and *Emmonsia* sp in South Africa.1,2 *Candida* spp commonly cause mucosal, oral, vaginal, and oesophageal infections in patients with stage 3 and 4 HIV disease, and fungal skin and nail infections are major causes of morbidity in HIV-infected individuals. However, mucosal candida infections usually readily respond to azole antifungal treatment and immune reconstitution with antiretroviral therapy (ART). In the era of ART, recurrent azole-resistant *Candida* spp infections are rare.

With widespread availability of ART and earlier testing and treatment for HIV, the incidence of systemic fungal infections has decreased in people living with HIV in high-income countries, although room for improvement remains.1 By contrast, in many regions with high HIV prevalence, particularly sub-Saharan Africa, there is little evidence for a substantial decrease in cases.3 Many patients present with advanced HIV and with a low CD4 cell count.3 Additionally, enrolment data from cryptococcal meningitis trials show that, although the total number of cases was stable over time, half or more of patients with cryptococcal meningitis had taken ART4 but had persistent low CD4 cell counts due to problems of retention in care and or ART resistance. Thus, further efforts to address the problem of fungal infections through rapid point-of-care diagnostics for these major fungal pathogens and global access to antifungal drugs are needed as an integral part of an effective response to the HIV pandemic.

Pneumocystis pneumonia

Epidemiology

Pneumocystis pneumonia has emerged as a major cause of infection in those with HIV/AIDS, and is estimated to count.1 Additionally, enrolment data from cryptococcal meningitis trials show that, although the total number of cases was stable over time, half or more of patients with cryptococcal meningitis had taken ART4 but had persistent low CD4 cell counts due to problems of retention in care and or ART resistance. Thus, further efforts to address the problem of fungal infections through rapid point-of-care diagnostics for these major fungal pathogens and global access to antifungal drugs are needed as an integral part of an effective response to the HIV pandemic.

Key messages

- Incidence of systemic fungal infections in patients with HIV/AIDS has decreased in many resource-rich areas after the introduction of antiretroviral therapy and earlier diagnosis and treatment of infection
- In many resource-limited settings incidence is not yet decreasing due to continued late diagnosis and challenges with retention in HIV care
- New PCR-based assays can distinguish colonisation from infection with pneumocystis
- Measurement of cerebrospinal fluid pressure is essential in cryptococcal meningitis, and management of raised cerebrospinal fluid pressure through careful therapeutic lumbar punctures reduces mortality
- In large parts of the world, HIV-related histoplasmosis is often neglected, undiagnosed, or misdiagnosed as tuberculosis, because of poor access to current diagnostics
- The intersection with HIV has transformed *Talaromyces marneffei* from a rare human pathogen to a major cause of HIV-associated death in southeast Asia; amphotericin B was shown to be superior to itraconazole as initial treatment in a large randomised trial
- Novel, affordable, point-of-care diagnostics for pneumocystis, histoplasmosis, and talaromycosis, and wider access to effective antifungals are urgently needed to reduce the burden of HIV-associated fungal infections in resource-limited settings


This is the first in a Series of eight papers about fungal infections

Mayo Clinic College of Medicine, Rochester, MN, USA (A H Limper MD); Inserm CIC 5424, Centre d’Investigation Clinique Antilles Guyane, Centre Hospitalier de Cayenne, Cayenne, France (A Adenis MD); Equipe EA 3593, Ecosystèmes Amazoniens et Pathologie Tropicale, Université de la Guyane, Cayenne, France

See


See

http://dx.doi.org/10.1016/S1473-3099(17)30444-0

See

http://dx.doi.org/10.1016/S1473-3099(17)30308-0

Lancet Infect Dis 2017; 17: e334–43
cause more than 400 000 cases worldwide every year.7 Many of these patients are undiagnosed or diagnosed late, particularly in resource-limited settings. The mortality of pneumocystis pneumonia ranges from 10% to 30% or higher, depending on the patient population, comorbidities, and whether the diagnosis is made early.10 Although the incidence has been reduced by implementation of ART, pneumocystis pneumonia continues to be a problem in patients who are unaware that they are infected with HIV and in those with ART failure or who stop taking ART.10

Pathogenesis

Pneumocystis spp are members of the Ascomycetous fungi. Each mammalian species can harbour at least one unique species of the Pneumocystis genus—eg, P jirovecii infecting human beings and Pneumocystis carinii infecting rats. Serological and epidemiological data indicate that most people are exposed and transiently infected with P jirovecii early in life.12 With healthy immune responses, this early infection is effectively cleared. However, during periods of immune suppression such as in patients with HIV who have CD4 counts lower than 200 cells per µL, the organism proliferates, leading to life-threatening pneumonia. CD4 immunity is essential for long-term control and memory responses to this fungus; contributing immunity is provided by innate immune responses, CD8 cells, and B-lymphocytes. In the absence of effective CD4-based immunity, innate inflammatory responses promote the accumulation of inflammatory cells, including neutrophils and CD8 lymphocytes, which strongly contribute to lung injury. Appreciation of this innate immune response has led to the use of adjunctive anti-inflammatory corticosteroids to moderate-to-severe pneumocystis pneumonia.13 Evidence suggests that infection can be acquired from other infected individuals. Therefore, whenever feasible, immunosuppressed patients should not be directly exposed to individuals with active pneumocystis pneumonia.14,15

Diagnosis

Most patients with pneumocystis pneumonia present with cough and progressive dyspnoea (initially on exertion) and pulmonary infiltrates on chest radiograph or lung imaging (figure 1A). Definitive diagnosis relies on identification of P jirovecii organisms in respiratory secretions or bronchoalveolar lavage samples (figure 1B). Experienced observers can identify the organisms using Wright-Giemsa stained smears. However, tinctorial methods including methenamine silver, Papanicolaou, cresyl echt violet, and Calcofluor white staining assists in rapid identification of organisms.16 Fluorescence staining with monoclonal antibodies further increases sensitivity to approximately 95% when applied to bronchoalveolar lavage samples.7

Over the past decade, many laboratories have switched to identification using PCR. Nested PCR has been useful to identify colonisation as well as clinical infection, whereas, single-copy real-time PCR assays have been devised to rapidly identify patients with clinical infection, rather than colonisation.17,18 In expensive point-of-care diagnostic strategies, which are technically less demanding, are needed for regions with limited resources.7 Work is ongoing to develop relevant pneumocystis antigen-detection systems and thermocycler independent amplification strategies that can be used in such settings.

β-D-glucan assays in the serum can be useful as a screening tool and adjunct to diagnosis because they have good sensitivity in patients with HIV and pneumocystis pneumonia. Although β-D-glucan testing does cross react with the glucans released from other fungi, high levels of β-D-glucan (>100 pg/mL) in patients with HIV in the appropriate clinical setting does provide evidence to support starting therapy.19

Figure 1: Features of Pneumocystis jirovecii pneumonia in patients with HIV
CT image of a 41 year old woman presenting with cough and dyspnoea (A). Imaging shows mixed alveolar and interstitial infiltrates, which were diagnosed as being due to Pneumocystis jirovecii pneumonia on bronchoalveolar lavage. Methenamine silver staining demonstrates typical pneumocystis organisms clustered in alveolar exudates (B).
Vast regions of the world including sub-Saharan Africa, Asia, and South America do not have ready access to laboratory facilities equipped for the diagnosis of pneumocystis pneumonia, rendering the true burden and impact of this infection under-recognised. For instance, when modern diagnostic methods were applied, unsuspected pneumocystis infection was found to be the cause of up to 7% of all severe pneumonia in children younger than 5 years in a hospital in southern Mozambique. In regions with few laboratory facilities, the diagnosis of pneumocystis is often made on clinical grounds. Although such an approach is pragmatic, it lacks specificity, which is necessary to rapidly focus the appropriate antibiotic therapy towards pneumocystis when it is present.

**Treatment**

The mainstay of therapy is intravenous co-trimoxazole (sulfamethoxazole-trimethoprim) with the trimethoprim dosed at 15–20 mg/kg per day and sulfamethoxazole at 75–100 mg/kg per day. This is given in four equally divided doses for 21 days. For patients with milder disease, and once the disease is under control, therapy can be safely switched from intravenous to oral administration. It is useful to monitor therapeutic trough levels to avoid toxicity and ensure benefit, although this is infrequently done. Often, clinical improvement is not noted for up to 1 week. Patients who cannot tolerate co-trimoxazole are usually treated with the combination of primaquine and clindamycin or pentamidine. Atovaquone is generally reserved for those with milder disease. Efavirenz significantly reduces atovaquone concentrations. Only co-trimoxazole is present on the WHO Model List of Essential Medicines for pneumocystis pneumonia, with the alternative drugs appearing on the complementary list and for other indications.

Adjunctive corticosteroid therapy is given to patients with moderate to severe pneumocystis pneumonia, as defined by a room air $\text{PaO}_2$ lower than 70 mm Hg or alveolar–arterial oxygen gradient higher than 35 mm Hg. For these individuals, prednisone is provided at 40 mg twice a day on days 1–5, 40 mg once a day on days 6–10, and then 20 mg once a day up to day 21. In children younger than 13 years, prednisone can be given at 1 mg/kg twice a day on days 1–5, 0·5 mg/kg twice a day on days 6–10, and finally 0·5 mg/kg once a day on days 11–21.

**Prevention**

Appropriate pneumocystis prophylaxis is essential to prevent the often-lethal infection. Patients who have CD4 counts lower than 200 cells per µL or a history of oropharyngeal candidiasis should receive prophylaxis with one double-strength co-trimoxazole tablet three times a week or one single-strength co-trimoxazole tablet once a day. Co-trimoxazole in low-income and middle-income countries has additional benefits by reducing early mortality from malaria, reducing anaemia, and improving growth in children. Alternatives for patients who cannot tolerate co-trimoxazole include dapsone, atovaquone, or dapsone with pyrimethamine and leucovorin. Dapsone should be used cautiously in individuals with glucose-6-phosphate dehydrogenase deficiency. Generally, prophylaxis can be discontinued when CD4 counts are consistently higher than 200 cells per µL for longer than 3 months. An effective pneumocystis vaccine is not yet available, but preclinical primate studies support the potential efficacy of such an approach for patients with HIV.

**Cryptococcosis**

**Epidemiology**

Latest estimates suggest that HIV-associated cryptococcal meningitis accounts for 150 000–200 000 deaths per year. These deaths occur mostly in sub-Saharan Africa where the associated mortality remains at around 70% at 3 months. Most HIV-associated infections are caused by *C neoformans*, although in Botswana, up to 30% of infections are with *Cryptococcus gattii*. Patients with cryptococcal meningitis present with headache and fever, with a median duration of 2 weeks between symptom onset and first presentation. Many patients develop nausea, vomiting, diplopia due to cranial nerve VI palsies, and reduced visual acuity related to raised cerebrospinal fluid pressure. If untreated, symptoms progress to abnormal mental status, reduced conscious level, seizures, and finally coma.

**Diagnosis**

Traditionally, diagnosis has relied on lumbar puncture. A cerebrospinal fluid India ink preparation is positive in 70–90% of patients with HIV-associated infections, and the remainder of patients can be reliably diagnosed by cryptococcal antigen (CrAg) detection or culture. However, headache is non-specific and lumbar puncture is frequently delayed, especially in resource-limited settings, until such time as the prognosis is poor. Development of a point-of-care lateral flow test for detection of CrAg is a major advance. Antigen is present in blood (serum, plasma, or whole-blood finger-prick sample) before the development of symptoms and the test is highly specific and more sensitive than previous latex agglutination assays. The test enables earlier diagnosis, even in primary care settings, and screening of patients in hospitals in high-prevalence areas. It also makes feasible screening and pre-emptive therapy as a strategy to prevent the development of meningitis after HIV diagnosis and before starting ART in those with low CD4 cell counts.

**Antifungal therapy**

The gold-standard antifungal therapy for cryptococcal meningitis is the combination of amphotericin B deoxycholate (D-AmB; 0·7–1·0 mg/kg per day) and
flucytosine (100 mg/kg per day in four divided doses) for the initial 2 weeks, followed by fluconazole (400–800 mg per day for 8 weeks, and 200 mg per day thereafter) for a minimum of 1 year and until immune reconstitution. Addition of flucytosine was associated with a 40% reduction in mortality compared with D-AmB alone. Prehydration with normal saline and pre-emptive replacement of potassium and magnesium is recommended to mitigate the toxicities of D-AmB, but anaemia remains an important problem where transfusion capacity is limited. Liposomal amphotericin B (L-AmB) at 3–6 mg/kg per day is as effective as and better tolerated than D-AmB. Studies are ongoing to assess whether L-AmB could be used in intermittent high doses, as for leishmaniasis, to provide a convenient and cost-effective induction treatment. With care taken to adjust doses in case of renal impairment, flucytosine is generally well tolerated in this patient population for 2 weeks.

**Complications**

Raised cerebrospinal fluid pressure caused by a blockage of cerebrospinal fluid reabsorption at the level of the arachnoid granulations is common in cryptococcal meningitis, with about a quarter of patients having a pressure greater than 35 cm H₂O. If untreated, high pressure is associated with increased mortality, but increasing evidence points to the effectiveness of careful therapeutic lumbar punctures. Only the most severely ill patients might require a temporary lumbar drain or ventricular shunt. High cerebrospinal fluid pressure can develop in the second and third weeks of treatment, despite effective sterilisation of the cerebrospinal fluid, meaning that a lumbar puncture should be repeated if symptoms persist or recur.

Recommendations are to start ART between 4 weeks and 6 weeks after starting antifungal therapy. This schedule is based on the findings of studies suggesting 3 days or 8 days is too soon and 6 weeks or later is probably unnecessarily late. Given that in many centres, half of cryptococcal meningitis cases now occur in ART-experienced patients, it is prudent to only switch to second-line ART in those thought to have ART resistance or re-start ART in those who have discontinued taking ART, after 4 weeks of antifungal therapy. Cryptococcal meningitis in patients with ART failure needs to be distinguished from patients with unmasking cryptococcal immune reconstitution inflammatory syndrome (IRIS) (in which presentation is precipitated by starting ART) and in whom ART should be continued. Frequent clinical review is needed given some overlapping toxic effects of antifungal and antiretroviral drugs.

Paradoxical cryptococcal IRIS occurs in 15–20% of patients who are treated for cryptococcal meningitis. These patients respond to treatment but later have a recurrence of symptoms, at a median of around 1 month after starting ART. In patients re-presenting with a recurrence of symptoms, cerebrospinal fluid pressure should be measured and managed, because raised pressure is common in cryptococcal IRIS. Re-introduction of induction antifungal therapy can be considered while cerebrospinal fluid culture results are pending and while alternative diagnoses are actively pursued. If cryptococcal IRIS remains the likely diagnosis, and the patient is deteriorating, then short courses of corticosteroids have been used successfully. By contrast, corticosteroids given with initial antifungal therapy are harmful. Although cryptococcal IRIS can be life-threatening, related mortality should be lower than recorded in earlier series because of increased awareness and more prudent timing of ART.

**Prevention**

The lateral flow CrAg test has made feasible a screen and pre-emptive flucytosine treatment strategy to prevent the development of meningitis in patients with low CD4 cell counts. 3–8% of individuals with a CD4 count lower than 100 cells per µL usually test positive on CrAg screening of blood samples. In a retrospective study from Cape Town, patients testing positive for CrAg had a high (28%) chance, without treatment, of developing meningitis in the first year of ART, whereas, of those who tested negative and were started promptly on ART, none went on to develop meningitis. Subsequent modelling suggested such a strategy could be highly cost-effective, and screening has been endorsed in WHO guidelines and introduced in South Africa and elsewhere. Prospective studies are underway, with one report demonstrating that such screening and pre-emptive fluconazole, combined with ART adherence support, led to a 28% reduction in mortality in patients with late-stage HIV in the first year of ART. However, further work is needed to optimise the treatment of CrAg-positive patients. Despite the success of fluconazole therapy, these patients still have higher mortality compared with those who are CrAg negative, and of some concern there have been reports of decreased susceptibility to fluconazole in some areas. Some patients, even though asymptomatic or minimally symptomatic, have evidence of meningitis if they agree to a lumbar puncture, and this risk is related to blood antigen titre. Studies are planned to ascertain if those with a high antigen titre in blood would benefit from more aggressive antifungal therapy.

**Histoplasmosis**

**Epidemiology**

Histoplasmosis is caused by *Histoplasma capsulatum*, a thermally dimorphic ascomycete. The mould form is distributed worldwide in moist and enriched soils containing bird droppings or bat guano. Autochthonous cases of HIV-associated histoplasmosis have been described on five continents, the Americas accounting for most cases, notably the central eastern USA and Latin America. However, HIV-associated histoplasmosis is more widespread than was previously thought and is probably neglected, undiagnosed, or misdiagnosed as
tuberculosis. In endemic areas, histoplasmosis occurs in 2–25% of patients with HIV/AIDS and represents the first AIDS-defining infection in up to 50–75% of patients with HIV. Mortality rates range between 10% and 60%, depending on whether the diagnosis is made by experienced physicians with adequate infrastructure and access to antifungals other than fluconazole.

**Pathogenesis**

Soil disruption aerosolises microconidia or mycelial fragments, which are inhaled and, at body temperature, convert into yeasts in the lungs. Infection might also develop when, years after the primary infection, quiescent organisms are reactivated during immunosuppression. Once in the lungs, *H capsulatum* survives phagocytosis in macrophages, facilitating its dissemination throughout the mononuclear phagocyte system. An early robust proinflammatory response (Th1/Th17) is required to control *H capsulatum* growth. Hence, people with HIV are at higher risk of disseminated histoplasmosis, an AIDS-defining disease, which is lethal if left untreated.

Environmental exposures to bird droppings or bat guano and history of exposure to chicken coops are associated with an increased risk of histoplasmosis. Host factors such as low CD4 count lower than 200 cells per µL, nadir CD4 count lower than 50 cells per µL, CD8 count lower than 50 cells per µL, absence of ART or systemic antifungal therapy, the first 6 months of ART, history of herpes simplex virus infection, and male sex are independently associated with histoplasmosis in people with HIV infection.

**Clinical features and diagnosis**

In AIDS, histoplasmosis usually presents as a disseminated disease (>95% of patients). All organs and tissues can be involved. Fever, fatigue, and weight loss are almost universal. Cough and dyspnoea are the most frequent localising symptoms, in association with diffuse radiological infiltrates, usually with a miliary reticulonodular pattern (figure 2A). Abdominal pain and diarrhoea are frequent and reflective of colonic ulcerations (figure 2C). Lymph node enlargement, hepatosplenomegaly, and mucocutaneous manifestations are diagnostic clues. Lactate dehydrogenase, liver enzymes (a higher concentration of aspartate aminotransferase than alanine aminotransferase), and ferritin elevation, with or without pancytopenia and haemophagocytosis syndrome, should lead to further investigations. Usually subacute (1–2 months), the disease evolution varies from latency to 10–20% fulminant severe forms (septic shock

---

**Figure 2: Features of histoplasmosis in patients with HIV**

- **A**: Chest radiograph showing a diffuse interstitial reticulonodular pattern in a patient with histoplasmosis. 
- **B**: Photograph of a lymph node enlargement in histoplasmosis. 
- **C**: Photographs of colonic ulcerations in a patient with histoplasmosis. 
- **D**: Giemsa-stained bone marrow smear showing the yeast phase of *Histoplasma capsulatum*. 
- **E**: Lactophenol blue-stained bone marrow culture showing the mould form of *H capsulatum*. Used with permission of P Couppié (A, B, C) and C Aznar (D, E) from Cayenne General Hospital, France.
with multiorgan failure), mainly in late presenters, with fatality rates reaching 50–70%.51,53

Direct examination with special staining (May-Grünwald Giemsa, periodic acid–Schiff, and Grocott-Gömöri’s methenamine-silver) and culture of all tissues or body fluids at room temperature are the gold standard methods for diagnosis.60 Bone marrow aspiration, blood culture, and tissue biopsies are all useful.51 Direct examination is rapid, but culture, which requires a biosafety level 3 laboratory, takes a median of 2 weeks, and maximum of 6 weeks. For both methods, sensitivity varies with sample type, disease severity, and operator experience.51 Antibody detection in cerebrospinal fluid is of most interest for the diagnosis of neuromeningeal forms.61 Although useful molecular tools are being developed, their place in care and treatment is still evolving.51 Detection of *H capsulatum* antigen is among the most sensitive and rapid means to diagnose disseminated histoplasmosis in AIDS.62 The non-invasive reference method in the USA has been a polyclonal quantitative *Histoplasma* spp antigen radio-immunoassay in urine, blood, and bronchoalveolar lavage, but it is unavailable in other endemic areas.51 However, a new commercially available monoclonal ELISA detecting galactomannan antigen in urine is being made widely available; with promising results.62,63 It is noteworthy that the highest yield is achieved through the combination of several diagnostic methods.

**Therapy**

In moderately severe to severe cases, intravenous L-AmB (3–4 mg/kg per day) is recommended for 2 weeks or until clinical improvement.64 An alternative lipid formulation of amphotericin B at the same dosage might be preferred over D-AmB (0–7 mg/kg per day) if L-AmB is unavailable. Continued treatment with oral itraconazole (200 mg three times a day for 3 days, followed by 200 mg twice a day) is given for at least 1 year.64 Patients with non-severe cases can be treated with itraconazole alone.64 Prevention is based on recommendations for workers at risk, and long-term suppressive therapy with itraconazole 200 mg a day as primary (only in the USA) or secondary prophylaxis.65 ART should be started promptly, within the month after antifungal therapy initiation.64 Nevirapine and efavirenz are moderate inducers of the CYP3A4 enzyme, and reduce the concentration of itraconazole.66 However, both itraconazole and its major metabolite hydroxyitraconazole are equally active antifungal drugs, and it is unclear whether itraconazole dose adjustment is needed. In view of these interactions, a randomly obtained serum level of at least 1·0 µg/mL of itraconazole is recommended after 2 weeks of therapy.64,67

Morbidity and mortality from histoplasmosis have increased, largely attributable to the spread of HIV.68 Although thousands are dying of a treatable disease, histoplasmosis is off the radar of international organisations involved in the fight against HIV/AIDS and tuberculosis.69 Hence, the global burden of histoplasmosis remains unknown and access to rapid and simple diagnostics and effective antifungals remains a challenge in low-income and middle-income countries.69,70

**Talaromyces (formerly penicilliosis)**

**Epidemiology**

*T marneffei* causes a life-threatening mycosis affecting primarily immunocompromised residents and travellers in southeast Asia, southern China, and northeastern India (figure 3).71,72 The intersection with HIV has transformed *T marneffei* from a rare human pathogen to a major cause of HIV-associated death, second only to tuberculosis and cryptococcosis or pneumocystis pneumonia in Thailand and Hong Kong.73,74 In Vietnam, talaromycosis makes up 4–11% of AIDS-related admissions75,76 and is the second most common cause of bloodstream infections after cryptococcosis.77 ART has led to a decline in incidence, but talaromycosis remains a major problem in people with undiagnosed and untreated HIV infection. Increasingly talaromycosis occurs outside endemic regions because of increased migration and international travel78 and a rise in use of chemotherapy and immunosuppression.79

**Ecology and transmission**

Pathogen reservoirs and disease acquisition are being elucidated. The bamboo rat is the only non-human host of *T marneffei* with a high frequency of asymptomatic infection.79–81 Isolates from bamboo rat and human beings have similar or identical genotypes.80,81 However, there is no evidence of direct bamboo-rat-to-human transmission; instead, occupational exposure to plants and animals has been associated with human

---

**Figure 3:** Geographical distribution of *Talaromyces marneffei* infection

- **Endemic areas**
- **Regions of highest incidence (>100 reported cases)**
- **Regions of imported or travel-associated cases**
infection.84 This association is recently confirmed in a large case-control study from Vietnam, which additionally revealed that residents from or travellers to highland areas are at increased risk.85 Incidence increases 30–50% during the rainy months,76,84 and can be predicted by humidity levels.85,86 T marneffei has been isolated from bamboo rat faeces and soil samples within bamboo rat burrows,87,88 and T marneffei DNA detected in elephant-associated soil.89 Collectively, these epiecological data suggest an interplay among multiple environmental reservoirs involving soil, plants, and animals, in which bamboo rats may be exploited by T marneffei to expand its biomass and biogeography.

Infections in people probably occur through inhalation of T marneffei conidia. The incubation period is estimated to be 1–3 weeks in acute disease, whereas reactivation disease can occur many years after exposure in immunocompromised hosts.

Clinical features and outcomes
Most infections with talaromycosis occur in patients with CD4 counts lower than 100 cells per µL. Patients typically develop disseminated disease with fever, weight loss, hepatosplenomegaly, lymphadenopathy, and respiratory and gastrointestinal abnormalities. Papulonecrotic skin lesions are present in 60–70% of patients (figure 4A). Common laboratory findings include anaemia, thrombocytopenia, and elevated transaminases.71,75,76 Concomitant opportunistic infections are common, particularly tuberculosis and salmonella infections.75,76 Case fatality rates in treated patients vary, from 10% in Thailand and Hong Kong79,80 to 33% in China and Vietnam,74,81 reflecting differences in time to diagnosis and access to ART. Some clinical and laboratory predictors of mortality include older age, shorter duration of symptoms, dyspnoea, absence of fever or skin lesions, thrombocytopenia, and increased lactate dehydrogenase concentrations.75,76

T marneffei-associated IRIS has been reported; commonly occurring as unmasking IRIS in patients starting ART. Skin lesions can be atypical, including erythematous nodules, verrucous lesions, or erythematous plaques.52,85 Prospective studies that define incidence, risk, and impact of talaromycosis IRIS are needed. Continuation of ART, antifungal therapy, and cautious use of non-steroidal anti-inflammatory medications are the main therapeutic approaches.

Diagnosis
Presumptive diagnosis can be made based on microscopic findings of intramacrophage and extramacrophage yeast organisms in smears of skin lesions, lymph node, or bone marrow aspirate (figure 4B). Definitive diagnosis is made by pathogen isolation from clinical specimens demonstrating thermal dimorphism (figure 4C). Culture can be slow (3–14 days), resulting in diagnostic delay and raised mortality, particularly in patients without skin lesions.73,76 PCR-based assays have been developed for rapid diagnosis;79,85 however, the sensitivities are insufficient (range 60–70%) to be considered widely applicable. Recently developed ELISA to detect T marneffei antigen appears to be more sensitive than blood culture and other diagnostic methods96,97 and should be further evaluated for clinical application. Point-of-care tests are urgently needed.

Antifungal therapy and prevention
D-AmB and itraconazole are effective drugs in talaromycosis, whereas T marneffei is resistant to fluconazole.75,76,90,91 The IVAP multicentre trial comparing D-AmB and itraconazole induction therapy reported mortality after 6 months of 11·3% and 21·0%, respectively (absolute risk difference 9·7%, 95% CI 2·8–16·6; p=0·006).98 L-AmB and voriconazole are also effective; however, these drugs are not available in resource-limited settings. International guidelines recommend D-AmB (0·6–1·0 mg/kg per day) for 2 weeks, followed by itraconazole 400 mg per day for 10 weeks, with itraconazole 200 mg per day continued until CD4 counts are higher than 100 cells per µL for at least 6 months.99 Primary

Figure 4: Features of talaromycosis in patients with HIV
Photograph of skin lesions in a patient with talaromycosis (A). Giemsa-stained touch skin smear showing oval-shape yeast organisms inside and outside of a ruptured macrophage (B). The arrowhead highlights the midline septum in a dividing yeast cell characteristic of Talaromyces marneffei. Morphology of T marneffei colonies and T marneffei cells grown at 25°C and at 37°C on Sabouraud agar medium (C).
prophylaxis with itraconazole reduces invasive fungal infections in patients with CD4 counts lower than 200 cells per µL, however, the strategy has not been widely adopted in Asia because of concerns about costs, toxic effects, drug resistance, and interactions.

Conclusion
Serious fungal infections continue to contribute considerably to HIV/AIDS-related mortality worldwide. For pneumocystosis, talaromycosis, and particularly histoplasmosis, affordable, rapid point-of-care diagnostic tests, as have been developed for cryptococcosis, are urgently needed. Antifungal drugs, including D-AmB, L-AmB, and flucytosine, need to be made much more widely available. D-AmB and flucytosine have been recently added to the WHO Model List of Essential Medicines. Such measures, together with continued international efforts for education and training in the management of fungal disease, have the potential to greatly improve patient outcomes.

Contributors
All authors planned the scope of the review. AHL, TSH, AA, and TL wrote the first drafts of the sections on pneumocystosis, cryptococcosis, histoplasmosis, and talaromycosis, respectively. All authors contributed to and edited the final manuscript.

Declaration of interests
TSH received an investigator award from Gilead Sciences, diagnostic tests for research from ImmunoMyologics, honoraria from Pfizer, and serves on the advisory board for Viamed. AA spoke for Janssen Pharmaceutical Companies of Johnson & Johnson (in 2016) and received serves on the advisory board for Viamet. AA spoke for Janssen Pharmaceuticals. AHL and TL report no competing interests.

Acknowledgments
TL is supported by the Hawaii Center for AIDS in the US and by the Joint Global Health Trial Grant funded by the Wellcome Trust, the Medical Research Council, and the Department for International Development in the UK. AA is supported by an “Investissement d’Avenir” grant managed by Agence Nationale de la Recherche (CEBA; reference ANR-10-LABX-0025), by the Agence Nationale de Recherche sur le SIDA et les hépatites virales—Agence autonome de l’Institut National de la Santé et de la Recherche Médicale (ANRS troterm number 12260) and by the European Union (PO FEDER 2007–2013, number Présage: 31362, Guyane Française).

References
11. Cushion MT. Are members of the fungal genus Pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above? PLoS Pathog 2010; 6: e1000099.


69 Neglected histoplasmosis in Latin America group. Disseminated histoplasmosis in Central and South America, the invisible elephant: the lethal blind spot of international health organizations. AIDS 2016; 30: 167–70.


